Table 2.

Changes in obesity-associated risk factors from baseline value after 12 and 24 weeks (mean ± SD of remaining patients at time points)

	Change after 12 weeks (n = 211)				Change after 24 weeks (n = 178)
	placebo	16 mg cathine	32 mg cathine	53.3 mg cathine	placebo	16 mg cathine	32 mg cathine	53.3 mg cathine
Total cholesterol, mg/dl	−0.0 ± 0.6	−0.4 ± 0.7	−0.3 ± 0.8	−0.5 ± 0.6	0.2 ± 0.6	−0.4 ± 0.6	−0.1 ± 0.8	−0.4 ± 0.7
(p value)	(0.6944)	(0.0004)	(0.0280)	(<0.0001)	(0.0307)	(<0.0001)	(0.5696)	(0.0017)
LDL-cholesterol, mg/dl	−0.1 ± 0.5	−0.3 ± 0.6	−0.1 ± 0.6	−0.5 ± 0.5	0.0 ± 0.6	−0.3 ± 0.5	−0.1 ± 0.8	−0.3 ± 0.6
(p value)	(0.1490)	(0.0008)	(0.1362)	(<0.0001)	(0.8621)	(0.0004)	(0.5427)	(0.0019)
HDL-cholesterol, mg/dl	0.0 ± 0.2	−0.0 ± 0.2	−0.0 ± 0.2	−0.0 ± 0.2	0.1 ± 0.2	0.0 ± 0.2	0.2 ± 0.4	0.0 ± 0.2
(p value)	(0.4984)	(0.4938)	(0.5744)	(0.1783)	(0.0066)	(0.8526)	(0.0076)	(0.2435)
Triglycerides, mg/dl	−0.0 ± 0.7	−0.3 ± 0.8	−0.1 ± 0.7	−0.1 ± 0.5	0.3 ± 0.9	−0.3 ± 0.8	−0.4 ± 0.7	−0.2 ± 0.5
(p value)	(0.8799)	(0.0395)	(0.2163)	(0.3553)	(0.0930)	(0.0101)	(0.0016)	(0.0392)
Fasting glucose, mg/dl	0.1 ± 0.7	0.1 ± 0.8	−0.0 ± 0.8	−0.1 ± 1.4	0.3 ± 1.2	0.0 ± 0.8	−0.2 ± 0.8	−0.4 ± 1.2
(p value)	(0.5703)	(0.2383)	(0.7789)	(0.5552)	(0.1710)	(0.9164)	(0.1088)	(0.0377)